Political Appointees Shouldn't Influence Approval Decisions, Califf Says
Executive Summary
FDA commissioner offers new details about why he left final decision on Sarepta's controversial Duchenne muscular dystrophy drug to FDA's expert bureaucrats.
You may also be interested in...
Gottlieb's Confirmation: Will Industry Ties Remain A Problem After The Hearing?
The US FDA commissioner does not generally get involved with day-to-day activities, former FDA chiefs say, but perception of bias could be a lasting problem.
Gottlieb's Confirmation: Will Industry Ties Remain A Big Deal After The Hearing?
The US FDA commissioner does not generally get involved with day-to-day activities, former FDA chiefs say, but perception of bias could be lasting problem.
Califf Sets Exit At FDA, Ostroff Could Return To Acting Commissioner Post
Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available Buy Reports
Need a specific report? 1000+ reports available Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: